Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, increased to RMB 18.6 million from 0 in the previous year, primarily due to an upfront payment from an intellectual property license and technology transfer agreement with Joincare Group [21] - Other income decreased by RMB 72.6 million or 51.3% to RMB 68.8 million compared to RMB 141.4 million in 2024, mainly due to lower bank interest income and changes in government grants [21][22] - Research and development expenses declined by 14.8% to RMB 212.9 million from RMB 249.8 million in 2024, reflecting cost control measures [22][23] - Administrative expenses were RMB 199.5 million, a decrease of 28.5% compared to RMB 153.2 million in 2024, attributed to lower employee costs and adjustments in management compensation [23] Business Line Data and Key Metrics Changes - The company remains focused on advancing its HBV functional cure program, which is the top clinical priority, with key data reported and studies progressing towards registrational development [3][4] - The partnership with Joincare Group for soralimixin allows the company to prioritize resources on HBV programs while advancing the non-HBV portfolio [4][6] Market Data and Key Metrics Changes - The company is leveraging the strong research ecosystem in China to enhance its discovery capabilities, with new research infrastructure established in Beijing and Shanghai [9][36] - The company is exploring partnership opportunities for its HIV program and soralimixin rights in China, indicating a strategic approach to market expansion [32][36] Company Strategy and Development Direction - The company is sharpening its portfolio focus and expanding discovery capabilities, including integrating AI-enabled discovery tools into research workflows [4][8] - A disciplined partnering strategy is being employed to advance non-core assets while maintaining focus on areas with the strongest near-term opportunities [10][11] - The company aims to align management incentives with long-term shareholder value by significantly reducing senior management's annual bonuses [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the HBV program's potential, with important data expected to emerge in the coming months to inform future development stages [19][39] - The company is committed to maintaining a strong cash position, with bank deposits and cash equivalents amounting to RMB 1,941 million, expected to support operations beyond 2028 [22] Other Important Information - The company has built a robust internal discovery platform and is expected to nominate key new programs from its discovery efforts this year [4][9] - The company is open to both partnerships and self-development for its discovery programs, depending on expertise and market potential [37] Q&A Session Summary Question: Expectations for data from ENRICH and ENHANCE studies - Management expects data to emerge throughout the year, looking for immunologic priming effects and enhanced response rates in specific patient subgroups [26][27][28] Question: Focus areas for expanded discovery capabilities - The company is exploring candidates beyond infectious diseases, targeting chronic diseases with unmet medical needs, with specific areas to be disclosed later [30][31] Question: Updates on partnering strategy for non-core assets - The company continues to explore partnerships for its HIV program and soralimixin rights in China, with ongoing discussions with potential partners [32]

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, increased to CNY 18.6 million from 0 in the previous year, primarily due to an upfront payment from a licensing agreement with Joincare Group [21] - Other income decreased by CNY 72.6 million or 51.3% to CNY 68.8 million compared to CNY 141.4 million in 2024, mainly due to lower bank interest income and changes in government grants [21][22] - Research and development expenses declined by 14.8% to CNY 212.9 million from CNY 249.8 million in 2024, reflecting cost control measures [22][23] - Administrative expenses were CNY 199.5 million, a decrease of 28.5% compared to CNY 153.2 million in 2024, attributed to lower employee costs and adjustments in management compensation [23] Business Line Data and Key Metrics Changes - The company focused on advancing its HBV clinical programs, which remain the top clinical priority, with key data reported and studies advancing towards registrational pathways [3][4] - The partnership with Joincare Group for soralimixin allows the company to prioritize resources on HBV programs while advancing non-HBV assets [4][6] Market Data and Key Metrics Changes - The company is leveraging China's strong research ecosystem to enhance its discovery capabilities, with new research infrastructure established in Beijing and Shanghai [9][10] - The collaboration with OpenBench integrates AI-enabled drug discovery tools, enhancing the company's ability to analyze biological targets and design therapeutic molecules [10] Company Strategy and Development Direction - The company aims to maintain strong alignment with shareholder interests by reducing senior management's annual bonuses significantly, reinforcing the link between management incentives and long-term shareholder value [5] - The strategy includes a combination-based approach for HBV treatment, focusing on BRII-179 and elebsiran, with ongoing Phase 2b studies to evaluate their effectiveness [12][18] - The company is exploring partnership opportunities for its HIV program and other non-core assets, indicating a disciplined partnering strategy [6][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong cash position, expecting current cash to support operations beyond 2028 while continuing to invest in core programs [22][23] - The company anticipates important milestones for its HBV program in the coming year, with data expected to inform the next stage of development [19][39] Other Important Information - The company has built a robust internal discovery platform and is expanding its capabilities to support future pipeline development [9][24] - The focus on chronic diseases and unmet medical needs indicates a strategic shift beyond infectious diseases [31][36] Q&A Session Summary Question: Expectations for data from ENRICH and ENHANCE studies - Management expects data to emerge throughout the year, looking for immunologic priming effects and enhanced response rates in specific patient subgroups [26][27] Question: Focus areas for expanded discovery capabilities - The company is exploring candidates in chronic diseases and common diseases with unmet medical needs, with specific areas to be disclosed later [30][31] Question: Updates on partnering strategy for non-core assets - The company continues to explore partnerships for its HIV program and other assets, with ongoing discussions with potential partners [32][36]

Financial Data and Key Metrics Changes - In 2025, the company's revenue increased to CNY 18.6 million from 0 in the previous year, primarily due to an upfront payment from a licensing agreement with Joincare Group [20] - Other income decreased by CNY 72.6 million or 51.3% to CNY 68.8 million compared to CNY 141.4 million in 2024, mainly due to lower bank interest income and changes in government grant income [21] - Research and development expenses declined by 14.8% to CNY 212.9 million from CNY 249.8 million in 2024, reflecting cost control measures [22] - Administrative expenses were CNY 199.5 million, a decline of 28.5% compared to CNY 153.2 million in 2024, attributed to lower employee costs and organizational optimization [23] - As of December 31, 2025, cash and cash equivalents were CNY 1,941 million, expected to support operations beyond 2028 [22] Business Line Data and Key Metrics Changes - The company focused on advancing its HBV functional cure program, which remains its top clinical priority, with key data reported and studies progressing towards registrational pathways [3][4] - The partnership with Joincare Group for soralimixin allows the company to prioritize resources on HBV programs while advancing non-HBV assets [4][5] Market Data and Key Metrics Changes - The company is leveraging China's strong research ecosystem to enhance its discovery capabilities, establishing labs in Beijing and Shanghai to support early-stage drug discovery [9][36] - The company is exploring partnership opportunities for its HIV program and other non-core assets, indicating a strategic approach to market engagement [32][38] Company Strategy and Development Direction - The company aims to maintain strong alignment with shareholder interests by reducing senior management's annual bonuses to approximately one quarter of their original level [5] - The strategy includes a disciplined partnering approach for non-HBV assets while focusing on areas with the strongest near-term opportunities [10][11] - The company plans to introduce new programs from its discovery platform and define its development strategy around them [24][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the HBV program's potential, expecting important data to emerge later this year to inform the next stage of development [40] - The company is aware of the competitive landscape and aims to differentiate its offerings while exploring the potential of its expanded discovery capabilities [29][36] Other Important Information - The company has made significant investments in building its internal research capabilities and integrating AI-enabled discovery tools into its workflow [8][9] - The company is open to both internal development and partnerships for its discovery programs, depending on expertise and market potential [38] Q&A Session Summary Question: Expectations for data from ENRICH and ENHANCE studies - Management expects data to emerge throughout the year, looking for immunologic priming effects and enhanced response rates in the ENRICH study, and a 10% or better response in the ENHANCE study compared to previous results [26][27][28] Question: Focus areas for expanded discovery capabilities - The company is expanding beyond infectious diseases to include chronic diseases with unmet medical needs, with specific areas to be disclosed later [30][31] Question: Updates on partnering strategy for non-core assets - The company continues to explore partnerships for its HIV program and other assets, with ongoing discussions with potential partners [32]

Core Insights - Brii Biosciences reported strong execution and strategic progress in 2025, particularly in advancing its hepatitis B virus (HBV) portfolio towards higher functional cure rates [2][5] - The company maintains a strong cash position of US$276.1 million as of December 31, 2025, providing financial flexibility for its strategic priorities [4][15] - Brii Bio is focused on disciplined financial management and aligning management incentives with long-term shareholder interests [13][15] Clinical Program Updates - The company presented promising 24-week post end of treatment data from its Phase 2b ENSURE study, indicating the potential of BRII-179 to improve functional cure outcomes [2][6] - The ENHANCE study protocol was amended to evaluate a simplified triple combination regimen aimed at reducing treatment duration while maintaining efficacy, with results expected in 2H 2026 [2][10] - Ongoing studies (ENSURE, ENRICH, and ENHANCE) are fully enrolled, with data readouts anticipated to inform future registrational development decisions [10][14] Discovery Program Updates - Brii Bio has expanded its discovery efforts, establishing in-house capabilities and wet lab operations in Beijing and Shanghai to leverage China's drug discovery ecosystem [3][12] - The company announced a strategic out-licensing agreement with Joincare Group for the commercialization of soralimixin in Greater China, retaining rights outside this region [11][22] - Collaboration with OpenBench aims to utilize AI to accelerate discovery efforts, with updates expected throughout 2026 [11][12] Financial Performance - The company reported a loss of RMB224.1 million for the year ended December 31, 2025, a decrease of 56.3% compared to the previous year, primarily due to reduced fair value losses and lower operating expenses [15][22] - Administrative expenses decreased by 28.5% to RMB109.5 million, attributed to organizational optimization and adjustments in management compensation [15][22] - Research and development expenses were RMB212.9 million, down 14.8% from the previous year, reflecting a focus on prioritizing HBV programs [15][22]

Summary of Vir Biotechnology Conference Call Company Overview - **Company**: Vir Biotechnology (NasdaqGS:VIR) - **Focus Areas**: Infectious diseases and oncology, utilizing the human immune system to combat diseases [3][4] Key Strategies and Developments - **Oncology Programs**: - Development of masked T-cell engagers for metastatic solid tumors, with three clinical stage programs [3] - Recent compelling data from the prostate cancer program (VIR-5500) presented at ASCO GU [5] - Ongoing registrational program in hepatitis delta with initial data expected by the end of the year [4] Prostate Cancer Program (VIR-5500) - **Clinical Data**: - Phase 1 trial involved late-stage metastatic prostate cancer patients, many with poor prognoses [5] - Notable patient case: 63-year-old male with extensive liver metastases showed total obliteration of lesions after 9 weeks of treatment [6] - Achieved 53% PSA 90s and 29% PSA 99s in patients treated with doses above 3,000 micrograms per kilogram [7][12] - **Safety Profile**: - Low levels of cytokine release syndrome (CRS) and off-tumor toxicity, indicating a favorable safety profile [11][12] Competitive Landscape - **Differentiation**: - VIR-5500's dual masking technology allows for targeted action in the tumor microenvironment, potentially setting it apart from competitors [10] - Initial focus on late-line therapy with plans to explore earlier lines of therapy in combination with enzalutamide [15][17] Partnership with Astellas - **Deal Highlights**: - 50-50 profit split in the U.S. and co-promotion agreement, aiming for rapid market entry [20] - Financial terms include $1.7 billion in milestones and royalties, with Astellas covering 60% of global development costs [21] Future Plans - **Clinical Trials**: - Plans to skip Phase 2 and move directly to pivotal trials for VIR-5500 next year [24] - Expansion cohorts to begin in Q2 2026 [24] Other Oncology Programs - **HER2 and EGFR Programs**: - HER2 program showed initial signs of activity with 50% tumor shrinkage in a small cohort [36] - EGFR program is in early stages of dose escalation, exploring multiple indications [43] Hepatitis Delta Program - **Efficacy Data**: - 66% of patients reached undetectable levels after 48 weeks; 90% after 96 weeks [48] - Combination regimen of antibody and siRNA shows significant efficacy compared to competitors [50] - **Market Position**: - Anticipation of increased awareness and diagnosis of hepatitis delta due to competitive landscape [49] Financial Position - **Cash Runway**: - Increased cash position with partnerships and financing, providing runway until Q2 2028 [56] - Focus on oncology and hepatitis delta as key priorities while exploring other programs [57] Market Perception - **Company Transformation**: - Transition from a COVID-focused company to an immuno-oncology company, with a strong vision and promising data supporting this shift [58]

Summary of Vir Biotechnology FY Conference Call Company Overview - **Company**: Vir Biotechnology (NasdaqGS:VIR) - **Focus**: Development of innovative therapies for serious diseases, particularly in oncology and infectious diseases Key Developments - **VIR-5500**: - Recent data disclosed showed impressive efficacy and safety profiles in a trial involving very sick patients, with 95% having pre-taxane treatment and a median of 4 prior therapies [2][3] - **Efficacy Metrics**: - PSA50 rate: 82% - PSA90 rate: 53% - PSA99 rate: 29% - RECIST ORR: 45% in a very sick patient population [4] - **Safety Profile**: - Utilizes a PRO-XTEN masking platform to enhance safety by activating T-cells only at the tumor site, allowing for higher dosing without significant toxicity [5][6] Partnership with Astellas - **Strategic Partnership**: - Astellas selected as a partner due to their experience in prostate cancer and alignment on speed to market [16][17] - The deal includes a 50/50 profit split and a total of $1.7 billion in milestones, with $240 million cash upfront [19] - Vir retains significant involvement in the program, allowing for cash flow to support other projects [18] Future Plans - **Expansion Cohorts**: - Plans to initiate expansion cohorts for late-line monotherapy and early-line combination therapies with enzalutamide [11] - Pivotal trials expected to start next year [11] Competitive Landscape - **T-cell Engagers (TCEs)**: - VIR-5500 positioned as a potential best-in-class TCE for prostate cancer, achieving a favorable balance of efficacy and safety compared to competitors [13] - Other TCEs have shown either high efficacy with toxicity issues or mediocre efficacy with good safety profiles [13] Pipeline Overview - **Clinical Assets**: - Licensed three clinical-stage assets from Sanofi, including HER2 (VIR-5818) and EGFR (VIR-5525), both in phase 1 [23] - Seven preclinical assets utilizing the PRO-XTEN technology are progressing rapidly [24] Hepatitis Delta Virus (HDV) Program - **Tobevibart and Elebsiran**: - Combination therapy showed an 88% target not detected rate after 96 weeks, indicating strong efficacy in treating HDV [30] - Registrational trials ongoing, with initial data expected in Q4 2026 [30] Market Opportunity - **HDV Patient Population**: - Estimated 60,000 viremic patients in the U.S. and double that in Europe, with high potential pricing due to the orphan disease status [34] - Pricing estimates range from $150K to $250K in the U.S. and €60,000 to €150,000 in Europe [34] Financial Position - **Cash Balance**: - Post-Astellas deal, cash balance is $783 million, extending runway into Q2 2028 [37] - Recent equity raise of $173 million to support TCE portfolio [37] Strategic Considerations - **Internal vs. External Development**: - Decisions made on a case-by-case basis, considering market size, competitive landscape, and required capabilities [39][40] Conclusion - Vir Biotechnology is positioned strongly in the oncology space with promising data for VIR-5500 and a strategic partnership with Astellas that enhances its development capabilities and financial flexibility. The company is also making significant strides in addressing unmet needs in HDV treatment, with a robust pipeline and a clear strategy for future growth.

Core Insights - Vir Biotechnology has announced significant partnerships and advancements in its pipeline, including a global collaboration with Astellas and promising Phase 1 data for its oncology program VIR-5500, which targets hard-to-treat cancers [2][4]. Pipeline Programs - The company is advancing several investigational therapies, including VIR-5500 for metastatic castration-resistant prostate cancer (mCRPC), with positive Phase 1 data indicating dose-dependent anti-tumor activity [4][7]. - The Phase 1 study of VIR-5818, targeting HER2, is ongoing, with response data expected in the second half of 2026 [4]. - The Phase 1 study of VIR-5525, targeting EGFR, continues to enroll participants as planned [5]. Chronic Hepatitis Delta (CHD) Program - Vir Biotechnology has licensed to Norgine the combination of tobevibart and elebsiran for treating CHD, aiming to reach patients globally [2][7]. - Phase 2 SOLSTICE data showed that the combination therapy achieved undetectable hepatitis delta virus RNA in 88% of participants at Week 96 [7]. - The ECLIPSE registrational program is designed to evaluate the safety and efficacy of tobevibart and elebsiran, with topline data from ECLIPSE 1 expected in Q4 2026 and from ECLIPSE 2 and 3 in Q1 2027 [21]. Financial Results - As of December 31, 2025, the company reported approximately $781.6 million in cash, cash equivalents, and investments, a decline of $29.1 million in Q4 2025 [9]. - Revenue for Q4 2025 was $64.1 million, a significant increase from $12.4 million in Q4 2024, primarily due to a $64.3 million license revenue from the Norgine agreement [10]. - The net loss for Q4 2025 was $(42.9) million, an improvement from a net loss of $(104.6) million in Q4 2024 [17]. Future Outlook - The company expects its cash reserves to fund operations into the second quarter of 2028, bolstered by the Astellas collaboration and equity investment [18]. - The company plans to initiate pivotal Phase 3 trials for its oncology programs in 2027, following the expansion of dose cohorts for VIR-5500 [7][8].

Summary of Vir Biotechnology FY Conference Call Company Overview - **Company**: Vir Biotechnology (NasdaqGS:VIR) - **Industry**: Biotechnology, focusing on infectious diseases and oncology - **Mission**: Harnessing the human immune system to combat diseases, including infectious diseases and cancer [2][3] Core Strategies and Pillars 1. **Hepatitis Delta Program**: - Aiming to deliver a transformational therapy for chronic hepatitis Delta, with a significant commercial opportunity in the U.S. and other regions [3][4] - Registration program for Hepatitis Delta is underway, with potential regulatory review expected in 2027 [4][16] - Estimated 174,000 viremic patients in key markets, with a global prevalence of about 7 million [6][9] 2. **T-cell Engagers for Oncology**: - Developing a clinical-stage lineup of dual-masked T-cell engagers targeting solid tumors, addressing high unmet needs [4][18] - Upcoming data on VIR-5500, a PSMA-targeting T-cell engager, expected in Q1 2026 [4][22] 3. **Discovery Engine**: - Focused on developing a pipeline of best-in-class preclinical T-cell engagers and cancer immunotherapies [5][30] - Utilizes a unique ProXTEN masking technology to enhance safety and efficacy of T-cell engagers [18][20] Key Data and Results - **Hepatitis Delta**: - Combination therapy of Tobevibart (monoclonal antibody) and elebsiran (siRNA) shows promising results, with 88% of patients achieving undetectable HDV RNA at 96 weeks [12][14] - Combination therapy demonstrated significant reductions in HBV surface antigen levels, critical for controlling the delta virus [13][15] - **Oncology**: - VIR-5500 has shown favorable efficacy and safety profiles in early trials, with low rates of cytokine release syndrome [22][25] - VIR-5818 (HER2-targeted) and VIR-5525 (EGFR-targeted) are also in development, with promising early efficacy signals [23][24] Financial and Strategic Partnerships - Entered a commercial license agreement with Norgine, including an upfront payment of EUR 550 million and milestone payments, which will help fund the Eclipse program [16][17] - Retained commercialization rights in the U.S. and other markets outside Greater China, indicating a strategic focus on growth in these regions [17] Future Milestones - Anticipated top-line data for the Eclipse studies in Q4 2026 and Q1 2027, with plans for rapid marketing authorization submission [31][32] - Continued focus on advancing the T-cell engager pipeline, with updates expected in early 2026 [32][33] Challenges and Considerations - Manufacturing scaling remains a focus, with expertise inherited from previous assets aiding in this process [39][40] - The company is not currently seeking additional opportunities in hepatitis B, focusing instead on existing programs [38] Conclusion Vir Biotechnology is positioned to make significant advancements in the treatment of hepatitis Delta and various cancers through its innovative therapies and strategic partnerships, with a strong pipeline and upcoming data expected to drive future growth and value creation [33]

Core Viewpoint - Vir Biotechnology has entered into an exclusive licensing agreement with Norgine Pharma UK Limited for the commercial rights to the combination treatment of tobevibart and elebsiran for chronic hepatitis delta (CHD) in Europe, Australia, and New Zealand, which is expected to enhance the commercialization efforts and extend the company's financial runway into Q4 2027 [1][2][5]. Financial Terms - Vir Biotechnology will receive an initial reimbursement payment of EUR 55 million and is eligible for up to EUR 495 million in clinical, regulatory, and sales milestones, along with tiered royalties on net sales in the licensed territory [1]. - Norgine will contribute approximately 25% of the ongoing external clinical development costs for the ECLIPSE registrational program [1]. Product Development - The combination of tobevibart and elebsiran is being evaluated as a potentially first-of-its-kind therapy for CHD, utilizing a human monoclonal antibody and a small interfering RNA (siRNA) to disrupt the viral lifecycle [2]. - Enrollment for the ECLIPSE 3 trial has been completed, which is a Phase 2b head-to-head trial comparing the combination treatment with bulevirtide in bulevirtide-naïve patients [3]. Clinical Data - Data from the Phase 2 SOLSTICE trial indicated that 66% of participants receiving the combination treatment achieved hepatitis delta virus (HDV) RNA target not detected (TND) after 48 weeks, with a high proportion of TND observed in patients with cirrhosis [4]. Regulatory Designations - The combination treatment has received Breakthrough Therapy and Fast Track designations from the U.S. FDA, as well as Priority Medicines (PRIME) and orphan drug designations from the European Medicines Agency (EMA) [9]. Market Context - Chronic Hepatitis Delta (CHD) is recognized as the most severe form of chronic viral hepatitis, with no approved treatments currently available in the U.S. and limited options in the European Union and globally [10].

Core Viewpoint - The latest data from the ENSURE Phase II study indicates significant potential for the BRII-179 therapeutic vaccine in achieving HBsAg clearance in patients with hepatitis B virus (HBV) infection, with sustained benefits observed over a 24-week follow-up period [1][2]. Group 1: Study Results - In the BRII-179 responder group, 58% (11 out of 19) achieved HBsAg clearance at the end of treatment (EOT), compared to only 17% (2 out of 12) in the non-responder group [2]. - After 24 weeks post-treatment, 42% (8 out of 19) of the BRII-179 responders maintained HBsAg clearance, while only 8% (1 out of 12) of non-responders did [2]. - Previous studies indicated that 50% (4 out of 8) of BRII-179 responders maintained HBsAg clearance 24 weeks after EOT, even with baseline HBsAg levels ranging from 1,514 to 3,086 IU/mL, suggesting the vaccine's efficacy in diverse patient populations [2]. Group 2: Ongoing Research - The company is conducting two additional Phase IIb studies: ENRICH, which evaluates BRII-179's role in inducing HBV-specific immunity, and ENHANCE, which assesses the effects of a combination therapy involving BRII-179, elebsiran, and PEG-IFNα [3]. - ENHANCE consists of two parts: one assessing the simultaneous administration of the three drugs for 48 weeks, and the other exploring a sequential approach with 24 weeks of BRII-179 and elebsiran followed by 24 weeks of combination therapy [3]. - Both studies have completed patient recruitment and are expected to report EOT data in 2026 [3].